- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Gilead to acquire Tubulis for up to $5bn | ||
| Mi | Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development | ||
| Di | Lilly's Foundayo approved by US FDA as oral GLP-1 for weight loss | ||
| Di | Marking World Health Day on 7 April | ||
| 02.04. | Roche opens new Swiss Institute of Human Biology research facility | ||
| 02.04. | ReproNovo appoints Mark Altmeyer as Chairman of the Board | ||
| 01.04. | Novartis to acquire Excellergy in deal worth up to $2bn | ||
| 01.04. | Poolbeg Pharma appoints Adrian Kilcoyne to Scientific Advisory Board | ||
| 31.03. | Pharma's content paradox: why more content is not the answer | ||
| 31.03. | Achieving comms excellence through personalised engagement | ||
| 31.03. | Novo Nordisk's Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes | ||
| 31.03. | Sandoz partners with Samsung Bioepis to develop up to five biosimilars | ||
| 30.03. | The digital age and the advance of AI - pushing communications to new heights | ||
| 30.03. | Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment | ||
| 30.03. | Ipsen appoints Michelle Werner as Executive Vice President, President of North America | ||
| 27.03. | Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development | ||
| 27.03. | PM Society Board welcomes Frankie Everson and Mark Wheeler | ||
| 26.03. | BMS' Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma | ||
| 26.03. | BOOST Pharma appoints Elaine Jones as Board Chair | ||
| 25.03. | Eisai and Biogen's new data shows Alzheimer's patients choose to stay on Leqembi long-term | ||
| 25.03. | PRGN adds OVID Health as Specialist Healthcare Member Agency | ||
| 24.03. | Scotland becomes first part of UK to screen all newborn babies for SMA | ||
| 24.03. | RedSail Technologies appoints Joy Neely as Chief Growth Officer | ||
| 23.03. | Novartis agrees on potential $3bn deal to buy Synnovations's breast cancer treatment | ||
| 23.03. | Prime appoints David Hogben as SVP, Omnichannel Strategy & Delivery |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.